Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 2,795 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

NCT01751048
Conditions
Leishmaniasis
Interventions
GLA-SE, LEISH-F3, MPL-SE, SE
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Smoking Cessation
Interventions
Standard Care (SC), Intensive Counseling (IC)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Conditions
Achilles Tendinopathy
Interventions
Blood Flow Restriction Training, Sham Blood Flow Restriction Training, Eccentric Exercise
Other
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Bragg, North Carolina
Conditions
Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
Interventions
XL184, temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 5 more
Conditions
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions
Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Conditions
Postmenopausal Osteoporosis
Interventions
Strength/Weight Training & Drug/Supplement, Drug/Supplement only
Other · Combination Product
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Kearney, Nebraska • Lincoln, Nebraska • Omaha, Nebraska + 1 more
Conditions
Heart Disease, Blocked Arteries, Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis
Interventions
MESENDO, placebo
Biological · Other
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Conditions
Overweight and Obesity
Interventions
PACE, Diet, App, Face-to-face
Behavioral · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Wichita, Kansas
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Empagliflozin + Linagliptin, Empagliflozin placebo + Linagliptin placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Gulf Shores, Alabama • Norwalk, California • San Diego, California + 24 more
Not listed Not applicable Interventional Accepts healthy volunteers

CGMIS 48-hour Feasibility Study

NCT05562206
Conditions
Type1diabetes
Interventions
CGMIS (Continuous Glucose Monitoring Infusion Set)
Device
Lead sponsor
Pacific Diabetes Technologies
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Renton, Washington
Conditions
Overweight, Obesity
Interventions
Macupatide, Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more
Conditions
Suicidal and Self-injurious Behaviour
Interventions
Dialectical Behavior Therapy, Individual and Group Supportive Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
13 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lumiliximab + FCR, FCR
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 5 more
Conditions
Brain and Central Nervous System Tumors
Interventions
dasatinib, temozolomide, placebo, radiation therapy
Drug · Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
207
States / cities
Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Ceralasertib, Durvalumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
27
States / cities
Mobile, Alabama • Chandler, Arizona • Los Alamitos, California + 24 more
Conditions
Prosthetic-joint Infection
Interventions
Benzoyl Peroxide Topical, Electrocautery surgical skin incision
Drug · Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Stage 2 Systolic Hypertension
Interventions
valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Endocarditis, Bacterial
Interventions
Daptomycin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Any Cancer Diagnosis
Interventions
Play Intervention, Questionnaires
Behavioral · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
4 Years to 10 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Pre-exposure Prophylaxis (PrEP) Adherence for Black MSM

NCT06661343
Conditions
HIV Prevention
Interventions
C4 Program, C4 + 3MV Program
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Conditions
Neutropenia, Sarcoma
Interventions
filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, topotecan hydrochloride, vincristine sulfate, conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 35 more
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Diabetes Mellitus, Diabetes, Autoimmune
Interventions
Cholecalciferol, Omega 3 fatty acid
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
6 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida